FDA
-
-
-
-
-
-
-
Amneal reports positive interim results for Parkinson's drug CREXONT
-
-
-
-
-
-
-
Amneal Receives U.S. FDA Approval for Iohexol Injection
-
-
-
-
-
-
-
Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR® (omalizumab)
-
-
-
-
-
-
-
Amneal Reports Second Quarter 2025 Financial Results
-
-
-
-
-
-
-
Amneal Pharmaceuticals (AMRX) Receives U.S. FDA Approval for Brekiya
-
-
-
-
-
-
-
Amneal Announces Expanded Coverage for CREXONT® (Carbidopa and Levodopa) to Enhance Access for Parkinson’s Disease Patients in the U.S.
-
-
-
-
-
-
-
Amneal Pharmaceuticals (AMRX) Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

